/

AIM

AIM ImmunoTech Inc.Closed

0.1699−0.01 −4.23%USD

NYSE American · as of Oct 13, 16:00 ETAfter hours 0.1670 −1.71%

Open

0.1779

Prev close

0.1774

Day range

0.16850.1786

52-week range

0.16852.79

Volume

593.63K0.12×

Mkt cap

6.78M

P/E ttm

—

Fwd P/E

-0.46

EPS ttm

-2.98

Div yield

0.00%

Earnings

—

From 52w high

−93.92%

Price Chart

Yahoo Finance · delayed

AIMOct 13, 2026O 0.1800H 0.1800L 0.1700C 0.1700−0.0100 (−5.56%)Vol 576.00K

SMA 500.2232
SMA 2000.5564

1Y change −93.21% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

AIM AIM ImmunoTech Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.56%
1 month: −22.73%
3 months: −37.04%
6 months: −70.69%
Year to date: −84.49%
1 year: −93.21%

Valuation & ownership

Market cap: 6.78M
Enterprise value: −870.88K
P/E (ttm): —
Forward P/E: -0.46
PEG ratio: 0.71
Price / book: 0.64
Price / sales (ttm): 71.35
EV / EBITDA: 0.08
EPS (ttm): -2.98
EPS (forward): -0.3700
Beta (5y monthly): 1.27
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 39.89M
Float: 27.64M
Short % of float: 3.54%
Short ratio (days): 0.12
Held by insiders: 0.51%
Held by institutions: 2.88%
Avg volume (3m): 4.76M
50-day average: 0.2250
200-day average: 0.5618
52-week change: −93.21%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 33.6
vs 50-day SMA: −23.84%
vs 200-day SMA: −69.45%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 7.27%
Realised vol (20d, ann.): 69.0%
From 52-week high: −93.91%
From 52-week low: 0.00%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

4.25

+2,401.47% implied

Low 1.50Median 4.25High 7.00

Recommendation trend

Now2 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About AIM ImmunoTech Inc.

Yahoo Finance profile

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 19
Headquarters: Ocala, FL, United States
Website: aimimmuno.com
Officers: Mr. Thomas K. Equels Esq., J.D., M.S. Executive Vice Chairman, CEO & President
Mr. Robert Dickey IV, B.A., M.B.A. Chief Financial Officer
Mr. Peter W. Rodino III, Esq., J.D.

SEAS

Seasonality · AIM

2007–2026 · monthly returns

Strongest month Jan +23.75%Weakest month Dec −14.32%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.8	-18.4	-35.2	-11.9	-21.2	-31.7	-10.7	-8.0	-21.7	-5.6			−84.5%
2025	0.0	-30.0	-14.3	-41.7	14.3	8.1	-66.2	-16.1	11.8	-23.4	-27.6	-25.7	−94.4%
2024	-4.5	-4.8	17.5	-12.8	-12.2	2.8	-2.7	-5.6	-20.6	-3.7	-11.5	-13.0	−54.5%
2023	67.7	0.0	-17.3	11.6	-4.2	45.7	-7.5	0.0	-25.8	0.0	2.2	-6.4	+41.9%
2022	-8.7	-15.5	49.3	-0.9	-13.3	-14.3	-6.4	-8.2	-13.4	-1.7	-28.1	-24.4	−66.3%
2021	13.4	11.3	0.4	-4.8	-4.6	4.4	-2.8	-1.4	-1.9	-11.4	-17.9	-37.4	−48.6%
2020	85.2	105.0	24.9	-18.7	34.6	-11.4	17.7	-22.9	-4.4	-3.7	-11.1	-2.7	+231.5%
2019	27.8	-21.7	-11.1	31.3	-52.4	-0.2	-46.5	-23.4	-57.8	-34.2	-20.0	35.0	−93.2%
2018	42.9	0.0	-20.0	-20.0	0.0	0.0	-9.4	-3.4	-17.9	0.0	-21.7	0.0	−48.6%
2017	0.0	-30.4	14.6	21.8	-11.9	-15.3	-16.0	-14.3	-11.1	-3.1	3.2	9.4	−49.3%
2016	12.5	55.6	-7.1	7.7	-14.3	0.0	8.3	-6.4	-13.7	-22.2	-16.3	-15.9	−28.1%
2015	-12.0	9.1	-4.2	13.0	-11.5	-13.0	0.0	-10.0	-5.6	-23.5	-7.7	-33.3	−68.0%
2014	63.0	-9.1	0.0	-17.5	0.0	-6.1	-9.7	-3.6	18.5	-9.4	-10.3	-3.8	−7.4%
2013	12.0	-21.4	-13.6	15.8	0.0	0.0	4.5	0.0	4.3	-8.3	-4.5	28.6	+8.0%
2012	120.0	-29.5	25.8	-17.9	-15.6	3.7	25.0	82.9	25.0	6.3	-9.4	-67.5	+25.0%
2011	0.0	-8.2	2.2	8.7	-6.0	-17.0	-7.7	-16.7	3.3	-9.7	-28.6	0.0	−59.2%
2010	17.9	3.0	8.8	4.1	-14.3	-28.8	12.8	-5.7	12.0	-7.1	-5.8	0.0	−12.5%
2009	13.9	-4.9	53.8	-11.7	218.9	50.3	-17.3	5.7	-9.9	-27.5	-17.2	-53.3	+55.6%
2008	5.3	3.7	-12.0	-8.2	4.5	14.3	-16.3	-3.0	-46.2	28.6	0.0	-20.0	−52.6%
2007	-5.0	-13.9	-9.4	0.0	-3.1	-16.5	0.8	-13.5	49.6	-8.1	-17.7	-41.5	−65.5%

INSD

Insider Activity · AIM

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Sep 15, 2026	Equels Thomas KOfficer and Director	Purchase at price 0.21 per share.	11K	$2.31K
Sep 14, 2026	Equels Thomas KOfficer and Director	Purchase at price 0.22 per share.	22K	$4.86K
Sep 13, 2026	Equels Thomas KOfficer and Director	Purchase at price 0.22 per share.	5.9K	$1.29K
Mar 11, 2026	Chemerow David IDirector	—	25K	—
Mar 11, 2026	Equels Thomas KChief Executive Officer	—	25K	—
Feb 4, 2026	Chemerow David IDirector	Stock Award(Grant) at price 1.23 per share.	2.8K	$3.44K
Jun 12, 2025	Equels Thomas KChief Executive Officer	Purchase at price 7.70 per share.	107	$824
Jun 11, 2025	Equels Thomas KChief Executive Officer	Purchase at price 0.08 per share.	103	$9
Apr 10, 2025	Mitchell William MDirector	Purchase at price 0.03 per share.	196.9K	$5.00K
Apr 10, 2025	Kellner Ted DDirector	Purchase at price 0.03 per share.	1.97M	$50.00K
Apr 10, 2025	Equels Thomas KChief Executive Officer	Purchase at price 0.03 per share.	1.97M	$50.00K
Apr 10, 2025	Kellner Ted DDirector	Purchase at price 0.03 per share.	1.97M	$50.00K
Apr 3, 2025	Rodino Peter W IiiChief Operating Officer	Purchase at price 0.09 per share.	500	$44
Apr 3, 2025	Equels Thomas KChief Executive Officer	Purchase at price 0.06 per share.	41K	$2.58K
Mar 13, 2025	Mitchell William MDirector	Stock Award(Grant) at price 0.12 per share.	44.9K	$5.21K
Mar 13, 2025	Chemerow David IDirector	Stock Award(Grant) at price 0.12 per share.	44.9K	$5.21K
Mar 13, 2025	Bryan Nancy KDirector	Stock Award(Grant) at price 0.12 per share.	44.9K	$5.21K
Mar 4, 2025	Equels Thomas KChief Executive Officer	Purchase at price 0.13 per share.	50K	$6.73K
Mar 3, 2025	Equels Thomas KChief Executive Officer	Purchase at price 0.12 per share.	83.3K	$10.00K
Mar 3, 2025	Equels Thomas KChief Executive Officer	Purchase at price 0.12 per share.	44K	$5.06K

AIM

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

AIM

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About AIM ImmunoTech Inc.

Seasonality · AIM

Insider Activity · AIM

Congress Trades · AIM

Investors Holding AIM

Investors Holding AIM

Congress Trades · AIM

Insider Activity · AIM

Seasonality · AIM

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About AIM ImmunoTech Inc.

Earnings & Dividends

News